Echinocandins Versus Azoles as First-line Therapy for the Treatment of Candidemia in Intensive Care Units
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 79
- 试验地点
- 1
- 主要终点
- Comparison of all cause hospital mortality on day 90 between echinocandins and azoles
研究概览
简要总结
Candidemia is the most frequent invasive fungal disease in intensive care units (ICUs). It remains a major health concern, considering its attributable mortality up to 40% in critically ill patients. Successful clinical outcome requires early diagnosis and effective antifungal therapy. Guidelines for the treatment of candidemia were published by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). According to these guidelines, echinocandins are the preferred first-line therapy for candidemia in critically ill patients. Considering the bibliography supporting this statement, the place of triazoles still needs to be defined in candidemia therapeutic arsenal. In this context, we are setting up a retrospective cohort study using Hospital database to compare the efficacy of echinocandins and azoles for the treatment of candidemia in intensive care units.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who had a diagnosis of candidemia during ICU stay and were treated with echinocandins or azoles
排除标准
- •Patients with neutropenia
- •Patients without antifungal treatment
- •Patients who received antifungal therapy for more than two days before candidemia diagnosis
- •Patients receiving liposomal amphotericin b or multiple antifungal agents as first-line therapy
- •Patients who received less than 4 days of antifungal therapy after candidemia diagnosis
研究组 & 干预措施
Echinocandin group
Echinocandin group is the group of patients who received echinocandins as first-line therapy for candidemia
干预措施: Echinocandin treatment (Drug)
Triazole group
Triazole group is the group of patients who received triazoles as first-line therapy for candidemia
干预措施: Triazole treatment (Drug)
结局指标
主要结局
Comparison of all cause hospital mortality on day 90 between echinocandins and azoles
时间窗: Mortality on day 90 after antifungal initiation
Comparison of all cause hospital mortality on day 90 between echinocandins and azoles
次要结局
- Comparison of treatment success on day 30 between echinocandins and azoles.(Treatment success on day 30 after antifungal initiation)